Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

by Landgren, Ola, Nadeem, Omar
Published 2023

Management of multiple myeloma during COVID-19 pandemic

by Jethava, YS, Fonseca, Rafael, Landgren, Ola
Published 2020

Biological determinants of health disparities in multiple myeloma

by Smith, Cheryl Jacobs, Ambs, Stefan, Landgren, Ola
Published 2018

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis

by Landgren, Ola, Devlin, Sean, Boulad, Mathieu, Mailankody, Sham
Published 2016

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends

by Vélez, Ramón, Turesson, Ingemar, Landgren, Ola, Kristinsson, Sigurdur Y, Cuzick, Jack
Published 2016

Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms

by Goldin, Lynn R, Björkholm, Magnus, Kristinsson, Sigurdur Y, Samuelsson, Jan, Landgren, Ola
Published 2009

Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls

by Rögnvaldsson, Sæmundur, Steingrímsson, Vilhjálmur, Turesson, Ingemar, Björkholm, Magnus, Landgren, Ola, Kristinsson, Sigurður Yngvi
Published 2020

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

by Landgren, Ola, Sonneveld, Pieter, Jakubowiak, Andrzej, Mohty, Mohamad, Iskander, Karim S., Mezzi, Khalid, Siegel, David S.
Published 2019

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

by Dogan, Ahmet, Siegel, David, Tran, Nguyet, Fu, Alan, Fowler, Jessica, Belani, Rajesh, Landgren, Ola
Published 2020

Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B cell lymphomas with plasmacy...

by Gao, Qi, Yellapantula, Venkata, Fenelus, Maly, Pichardo, Janine, Wang, Lu, Landgren, Ola, Dogan, Ahmet, Roshal, Mikhail
Published 2018

Fractures and survival in multiple myeloma: results from a population-based study

by Thorsteinsdottir, Sigrun, Gislason, Gauti, Aspelund, Thor, Sverrisdottir, Ingigerdur, Landgren, Ola, Turesson, Ingemar, Björkholm, Magnus, Kristinsson, Sigurður Y.
Published 2020

Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III

by Rubio-Tapia, Alberto, Ludvigsson, Jonas F., Choung, Rok Seon, Brantner, Tricia L., Rajkumar, S. Vincent, Landgren, Ola, Murray, Joseph A.
Published 2016

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study

by Lindqvist, Ebba K., Landgren, Ola, Lund, Sigrún H., Turesson, Ingemar, Hultcrantz, Malin, Goldin, Lynn, Björkholm, Magnus, Kristinsson, Sigurdur Y.
Published 2016

mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies

by Rustad, Even H., Nadeu, Ferran, Angelopoulos, Nicos, Ziccheddu, Bachisio, Bolli, Niccolò, Puente, Xose S., Campo, Elias, Landgren, Ola, Maura, Francesco
Published 2021

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer...

by Chang, Vicky C., Khan, Ali A., Huang, Wen-Yi, Katki, Hormuzd A., Purdue, Mark P., Landgren, Ola, Hofmann, Jonathan N.
Published 2022

Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis

by Gadalla, Shahinaz M., Pfeiffer, Ruth M., Kristinsson, Sigurdur Y., Björkholm, Magnus, Hilbert, James E., Moxley, Richard T., Landgren, Ola, Greene, Mark H.
Published 2013

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

by Usmani, Saad Z., Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Shu, Xiaomei, Li, Chuang, Dimopoulos, Meletios
Published 2023

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study

by Biran, Noa, Siegel, David, Berdeja, Jesus G., Raje, Noopur, Cornell, Robert Frank, Alsina, Melissa, Kovacsovics, Tibor, Fang, Belle, Kimball, Amy S., Landgren, Ola
Published 2019

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

by Hultcrantz, Malin, Rustad, Even Holth, Yellapantula, Venkata, Arcila, Maria, Ho, Caleb, Syed, Mustafa H., Papaemmanuil, Elli, Zhang, Yanming, Maura, Francesco, Landgren, Ola
Published 2020

Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients

by Engels, Eric A., Jennings, Linda W., Everly, Matthew J., Landgren, Ola, Murata, Kazunori, Yanik, Elizabeth L., Pfeiffer, Ruth M., Onaca, Nicholas, Klintmalm, Goran B.
Published 2018